Q2 2017 EPS Estimates for Arena Pharmaceuticals, Inc. Cut by Analyst

Q2 2017 EPS Estimates for Arena Pharmaceuticals, Inc. Cut by Analyst


Arena Pharmaceuticals, Inc. - Stock analysts at Leerink Swann lowered their Q2 2017 earnings estimates for shares of Arena Pharmaceuticals in a report issued on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings per share of for the quarter, down from their prior forecast of .



from Biotech News